ArticleNeuro-oncology2019
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Article in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,547 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study
Role of Repeat Resection in Recurrent Glioblastoma (4rGBM) Trial: a Randomized Care Trial for Patients With Recurrent GBM
Who cites it
1,547 citing papers in PubMed, 8 syntheses or guidelines pooled it, 2,587 citations in OpenAlex.
- Socioeconomic disparities in vestibular schwannoma diagnosis and management: A systematic review.Neurosurgical review · 2026Pooled it
- Successful pre-operative endovascular intraventricular meningioma embolization: a systematic review and pediatric case analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Surgical strategies and long-term survival for third ventricle chordoid gliomas: a systematic review and clinical algorithm.Neurosurgical review · 2026Pooled it
- The clinical benefit of adding anlotinib to chemoradiothearpy in high-grade gliomas: a systematic review, meta-analysis, and specific analysis on glioblastoma.Clinical and experimental medicine · 2026Pooled it
- Single session versus hypofractionated stereotactic radiosurgery for large meningiomas (> 8 cc): a systematic review and meta analysis.Journal of neuro-oncology · 2025Pooled it
- Hypoglossal nerve palsy due to periarticular cyst extending into hypoglossal canal: a systematic review.Neurosurgical review · 2025Pooled it
- Slicing through complexity: a systematic review assessing the efficacy and safety of water-jet dissection in neurosurgical procedures with technical suggestions.Neurosurgical review · 2025Pooled it
- The safety and efficacy of VEGFR tyrosine kinase inhibitors for patients with gliomas: a systematic review, meta-analysis, and a specific analysis on glioblastoma.Neurosurgical review · 2025Pooled it
- Trial
- Predictions and cross-center validation of IDH status and 1p/19q status in adult diffuse glioma with non-invasive magnetic resonance spectroscopy.Magnetic resonance letters · 2027Article
- Trichodermin exhibits potent anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, suppressing invasion, and enhancing temozolomide efficacy.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Ferritin-Based Nanomotors for Deep Glioblastoma Penetration and Enhanced Drug Delivery.Macromolecular bioscience · 2026Article
- Late surgical site hemorrhage is a possible radiologic indicator of early tumor recurrence in grossly totally resected high-grade meningioma: A case report.Radiology case reports · 2026Article
- Radiation-induced cranial meningiomas are associated with earlier relapse: a propensity score-matched cohort study.Journal of neuro-oncology · 2026Article
- Recurrent C19MC-altered embryonal tumors with multilayered rosettes: outcomes of stereotactic radiosurgery.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy.CNS neuroscience & therapeutics · 2026Review
- Automated deep learning-based segmentation and volumetric analysis of meningiomas.Neuroradiology · 2026Article
- Role of CXCR4 PET Imaging for the Evaluation of Gliomas: A Comprehensive Literature Review.Cancers · 2026Review
- 1-Piperidine Propionic Acid Inhibits PAR2/SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness.International journal of molecular sciences · 2026Article
- Acute kidney injury during treatment of pediatric brain tumors: a retrospective analysis of survivors.Pediatric research · 2026Article
1,487 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 23.41 (Malignant AAAIR = 7.08, non-Malignant AAAIR = 16.33). This rate was higher in females compared to males (25.84 versus 20.82), Whites compared to Blacks (23.50 versus 23.34), and non-Hispanics compared to Hispanics (23.84 versus 21.28). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.6% of all tumors), and the most common non-malignant tumor was meningioma (37.6% of all tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.06. An estimated 86,010 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US in 2019 (25,510 malignant and 60,490 non-malignant). There were 79,718 deaths attributed to malignant brain and other CNS tumors between 2012 and 2016. This represents an average annual mortality rate of 4.42. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.8%, and the five-year relative survival rate following diagnosis of a non-malignant brain and other CNS tumors was 91.5%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.